ANDAs Must Show Different Inactive Ingredients Do Not Affect Efficacy - FDA
This article was originally published in The Tan Sheet
Executive Summary
Applications for generic drug products with different inactive ingredients than the innovator drug must demonstrate that efficacy is unaffected, FDA says in a proposed rule revising the regulation on bioequivalence/bioavailability and the content and format of abbreviated new drug applications.